Antibiotic resistance crisis: so bad, it's good?
This article was originally published in Scrip
Around 25,000 people in the EU (including 5,000 children) and 23,000 in the US die each year as a direct result of infections from resistant bacteria, according to estimates by the US Centers for Disease Control and Prevention (CDC) and the European Commission. With the dearth of new antibiotics coming through industry pipelines, it seems likely that these numbers will rise. According to Dr Neil Murray, CEO of Redx Pharma (which has an anti-infectives subsidiary focused on developing new compounds for resistant bacteria), this bad news has a silver lining.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.